Date Title and Summary Additional Formats
Toggle Summary NantKwest Announces FDA Authorization of IND Application for Mesenchymal Stem Cell Product for the Treatment of Severe COVID-19 Patients
Preliminary data from NantKwest collaborators suggests mesenchymal stem cell treatments may benefit COVID-19 patients with acute respiratory distress syndrome and cytokine storm Trial anticipated to initiate in Los Angeles area hospitals in Q2 Proprietary automated “GMP-in-a-Box”, an in-house
Toggle Summary NantKwest and ImmunityBio to Initiate a Phase 2 Study of Immunotherapy for Metastatic Pancreatic Cancer
Open-label, randomized Phase 2 study will evaluate combination immunotherapy, including NantKwest’s PD-L1 tumor-targeted natural killer cells and ImmunityBio’s IL-15 superagonist N-803 with standard of care versus standard of care alone Metastatic pancreatic cancer patient treated with PD-L1 t-haNK
Toggle Summary NantKwest and ImmunityBio to Present at the Bank of America Merrill Lynch Global Healthcare Conference
EL SEGUNDO, Calif. --(BUSINESS WIRE)--Apr. 29, 2020-- NantKwest, Inc. (NASDAQ: NK) and ImmunityBio, Inc. , today announced that Patrick Soon-Shiong , M.D., Chairman and CEO of both companies, will present at the virtual Bank of America Merrill Lynch Global Healthcare Conference on May 14, 2020 at
Toggle Summary NantKwest and ImmunityBio Announce Therapeutics and Vaccines for Combatting COVID-19; Clinical Trials Anticipated to Begin This Quarter
Immunotherapy companies led by Dr. Patrick Soon-Shiong are developing potential coronavirus therapeutics and vaccines to address the evolving stages of disease from moderate infection to severe acute respiratory distress syndrome (SARS) Vaccine Vector to Protect Against SARS-CoV-2 Infection:
Toggle Summary NantKwest Doses First Patient in Phase 2 Single-Arm Trial of Metastatic Merkel Cell Carcinoma Therapy With Off-the-Shelf CD16 Natural Killer Cells
Clinical trial for patients failing checkpoint therapy uses combination of first-in-class, cryopreserved, CD16 NK cells, ImmunityBio’s IL-15 superagonist and checkpoint inhibitor Avelumab EL SEGUNDO, Calif. --(BUSINESS WIRE)-- NantKwest, Inc. (Nasdaq: NK), a next-generation, clinical-stage
Toggle Summary Progress Report on Cancer Breakthroughs 2020 Project Presented by Dr. Soon-Shiong at J.P. Morgan Healthcare Conference
Complete Responses Noted in Multiple Tumor Types (including Pancreatic Cancer, Triple Negative Breast Cancer, Head and Neck Cancer, Merkel Cell Cancer, Bladder Cancer, and Non-Hodgkin’s Lymphoma) when Natural Killer cells and T cells are activated simultaneously FDA Registrationfilings in Bladder,
Toggle Summary NantKwest and ImmunityBio Announce Complete Response in Metastatic Pancreatic Cancer in the First Patient to Receive PD-L1 Tumor-Targeted Natural Killer Cells (PD-L1.t-haNK) Combined with N-803 IL-15 Fusion Protein
World’s first combination of tumor-targeted, off-the-shelf PD-L1-targeted Natural Killer cells with IL-15 fusion protein (N-803) to induce immune system activation of both the NK and T-cells demonstrated complete response in second-line metastatic pancreatic cancer, confirmed by PET/CT scan.
Toggle Summary ImmunityBio to Present at the 38th Annual J.P. Morgan Healthcare Conference
Company Chairman and CEO to Present Clinical Status Report on QUILT Cancer Breakthrough 2020 Trials in Multiple Tumor Types and Data Update on the Company’s N-803 IL-15 Superagonist, which Recently Received Breakthrough Therapy Designation from the FDA    CULVER CITY, Calif., January 7, 2020  – 
Toggle Summary NantKwest and ImmunityBio Present Results of Landmark Trial of First-in-Human Natural Killer Cell Combination Immunotherapy With Durable, Complete Response Data and 78% Disease Control in Refractory Triple Negative Breast Cancer at SABCS
World’s first combination of off-the-shelf NK with checkpoint inhibitor plus antigen simulation via adenovirus to induce immune system activation Ongoing durable complete responses ranging from 8 to 11 months observed in TNBC patients who failed standard of care Disease control rate of 78% and
Toggle Summary NantKwest Announces Phase 1 Results for First-in-Human PD-L1 Tumor-Targeted Natural Killer Cells (PD-L1.t-haNK) in Patients with Locally Advanced or Metastatic Solid Cancers
First-in-human trial shows no dose-limiting toxicities in six subjects treated as out-patients with PD-L1.t-haNK off-the-shelf CAR NK cell therapy with potential to overcome limitations of CAR-T therapies for solid tumors CULVER CITY, Calif. --(BUSINESS WIRE)--Dec. 2, 2019-- NantKwest, Inc.

Data Provided by Refinitiv. Minimum 15 minutes delayed.